OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 701 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... March 10, 2025 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Breast Cancer Patients with Low Breast Density May Be More Likely... January 18, 2021 Pride 2023: Taking on the inequalities in LGBTQ+ cancer care June 23, 2023 Load more HOT NEWS For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Heartburn Medications Pulled From Shelves Because They May Cause Cancer Michelle Mitchell: Cancer is a fixable problem Five Questions With…Fern, Christina, Mary, and Shelley.
